| Frontiers in Pharmacology | |
| Bayesian model-guided antimicrobial therapy in pediatrics | |
| Pharmacology | |
| Haden T. Bunn1  Lindsey M. Floryance1  Jogarao V. S. Gobburu2  | |
| [1] Pumas-AI, Inc., Centreville, VA, United States;Pumas-AI, Inc., Centreville, VA, United States;School of Pharmacy, University of Maryland, Baltimore, MD, United States; | |
| 关键词: pediatrics; antimicrobials; bayesian; precision dosing; therapeutic drug monitoring; | |
| DOI : 10.3389/fphar.2023.1118771 | |
| received in 2022-12-07, accepted in 2023-06-12, 发布年份 2023 | |
| 来源: Frontiers | |
PDF
|
|
【 摘 要 】
Antimicrobials have transformed the practice of medicine, making life-threatening infections treatable, but determining optimal dosing, particularly in pediatric patients, remains a challenge. The lack of pediatric data can largely be traced back to pharmaceutical companies, which, until recently, were not required to perform clinical testing in pediatrics. As a result, most antimicrobial use in pediatrics is off-label. In recent years, a concerted effort (e.g., Pediatric Research Equality Act) has been made to fill these knowledge gaps, but progress is slow and better strategies are needed. Model-based techniques have been used by pharmaceutical companies and regulatory agencies for decades to derive rational individualized dosing guidelines. Historically, these techniques have been unavailable in a clinical setting, but the advent of Bayesian-model-driven, integrated clinical decision support platforms has made model-informed precision dosing more accessible. Unfortunately, the rollout of these systems remains slow despite their increasingly well documented contributions to patient-centered care. The primary goals of this work are to 1) provide a succinct, easy-to-follow description of the challenges associated with designing and implementing dose-optimization strategies; and 2) provide supporting evidence that Bayesian-model informed precision dosing can meet those challenges. There are numerous stakeholders in a hospital setting, and our intention is for this work to serve as a starting point for clinicians who recognize that these techniques are the future of modern pharmacotherapy and wish to become champions of that movement.
【 授权许可】
Unknown
Copyright © 2023 Bunn, Gobburu and Floryance.
【 预 览 】
| Files | Size | Format | View |
|---|---|---|---|
| RO202310101780776ZK.pdf | 1121KB |
PDF